clinical trial · NCT06540261
The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer
Ono Pharmaceutical Co., Ltd.·phase1·active not recruiting·n = 65
Unresectable Colorectal CancerONO-7913ONO-4538FluorouracilOxaliplatinLevofolinateBevacizumabCetuximab
brief summary
To confirm the tolerability and safety of combined administration of ONO-7913, ONO-4538 and the standard of care FOLFOX in combination with bevacizumab or cetuximab as first-line treatment in patients with unresectable advanced or recurrent colorectal cancer
started
Sep 23, 2021
primary completion
Dec 31, 2027
completion
Dec 31, 2027
last updated
Oct 7, 2026
official title
An Open-label, Uncontrolled Study of ONO-7913, ONO-4538 and the Standard of Care FOLFOX in Combination With Bevacizumab or Cetuximab as First-line Treatment in Patients With Unresectable Advanced or Recurrent Colorectal Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol